Author:
Medina Castillo Diana Elizabeth,Hinojosa Ruiz Araceli,Aguilar Medina Diana Alejandra,La Cruz Medina Rodrigo De
Abstract
Inflammatory bowel disease (IBD) is a chronic immune-mediated disorder comprised of Crohn's disease and ulcerative colitis. Ulcerative colitis affects the large intestine, while Crohn's disease can affect any part of the gastrointestinal tract (GIT). IBD is a multisystem condition that predominantly affects the gastrointestinal, musculoskeletal, ocular, and cutaneous systems. The following dermatological manifestations associated with IBDs have been identified: Specific manifestations with the same histological features of the underlying only ocurrs in Crohn Disease (CD); cutaneous disorders associated with IBD aphthous stomatitis, erythema nodosum; reactive mucocutaneous manifestations of IBDs pyoderma gangrenosum, Sweet’s syndrome, bowel-associated dermatosis-arthritis syndrome, aseptic abscess ulcers, pyodermatitis y mucocutaneous conditions secondary to treatment including injection site reactions y eczema and manifestations due to nutritional malabsorption such as stomatitis, glossitis, angular cheilitis hair and nail abnormalities. We believe dermatological examination is essential in all IBD patients, especially in candidates to biologic therapies, in whom drug-induced cutaneous reactions may assume marked clinical relevance, such as psoriasiform eruption. One of the cutaneous manifestations associated with UC is pyoderma gangrenosum (PG), which is an inflammatory neutrophilic dermatosis that clinically presents with well-defined ulcers with an erythematous border and mucopurulent or hemorrhagic exudate.We present the case of a 44-year-old female patient, who presented non-specific chronic ulcerative colitis (UC) with active intestinal symptoms, fever, diarrhea and hematochezia, 20 days later it began with pustules on the head, trunk and extremities, which evolved into an ulcer with a border erythematous and well defined whose clinical and histopathological diagnosis corresponded to pyoderma gangrenosum.
Reference22 articles.
1. The Mexican consensus on the diagnosis and treatment of ulcerative colitis;Yamamoto Furushoa;Rev Gastroenterol Méx,2018
2. Immunopathogenesis of IBD: current state of the art;Souza HSP;Nat Rev Gastroenterol Hepatol,2016
3. Chávez Alvarez S, Gómez Flores M, Ocampo Candiani J. Cutaneous manifestations in inflammatory bowel disease. Gac Med Mex. 2016;152:622-630.
4. Extraintestinal manifestations in inflammatory bowel disease, epidemiology, genetics, and pathogenesis;Greuter;Expert Rev Gastroenterol Hepatol,2019
5. Dermatological manifestations in inflammatory bowel diseases;Antonelli;J Clin Med,2021